Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | TERT | O14746 | 3/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267034 | 1.00 | TSHR (0.45) | TSHRALDH1A1TP53PPARGMAPT | |
| SCHEMBL10669112 | 0.89 | PPARG (0.52) | ALDH1A1PPARGMAPTCYP19A1FFAR1 | |
| SCHEMBL10870024 | 0.89 | PPARG (0.52) | ALDH1A1PPARGMAPTCYP19A1FFAR1 | |
| SCHEMBL13749756 | 0.87 | — | — | |
| SCHEMBL1905028 | 0.85 | — | — | |
| SCHEMBL666560 | 0.85 | — | — | |
| SCHEMBL666559 | 0.85 | — | — | |
| SCHEMBL20630930 | 0.83 | TSHR (0.38) | TSHRALDH1A1TP53 | |
| SCHEMBL28393723 | 0.81 | ALDH1A1 (0.50) | TSHRALDH1A1TP53PPARGMAPT | |
| SCHEMBL4814932 | 0.81 | ALDH1A1 (0.67) | TSHRALDH1A1PPARGMAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872137-B2 | coupling of N-3-hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride with (E)-4-octene-1,8-dioic acid dichloride, in a solvent(dichloromethane), to obtain raw mivacurium chloride, water extraction of raw product, treatment with amberlite\" (tradename) absorbent resin, recovery of 97.5% pure product | FARMABIOS S.P.A. (IT) | 2011-01-18 | — | — | US | claimed |
| US-20070293534-A1 | Process for the preparation of mivacurium chloride | FARMABIOS S.P.A. | 2007-12-20 | — | — | US | claimed |
| CN-110698398-B | Purification method of mikui ammonium chloride | 武汉嘉诺康医药技术有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-110698398-A | Purification method of mikui ammonium chloride | 武汉嘉诺康医药技术有限公司 | 2020-01-17 | — | — | CN | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| WO-2013021398-A2 | A PROCESS FOR PREPARATION OF MIVACURIUM CHLORIDE | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021398-A2 | A PROCESS FOR PREPARATION OF MIVACURIUM CHLORIDE | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-7872137-B2 | coupling of N-3-hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride with (E)-4-octene-1,8-dioic acid dichloride, in a solvent(dichloromethane), to obtain raw mivacurium chloride, water extraction of raw product, treatment with amberlite\" (tradename) absorbent resin, recovery of 97.5% pure product | FARMABIOS S.P.A. (IT) | 2011-01-18 | — | — | US | disclosed |
| US-7872137-B2 | coupling of N-3-hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride with (E)-4-octene-1,8-dioic acid dichloride, in a solvent(dichloromethane), to obtain raw mivacurium chloride, water extraction of raw product, treatment with amberlite\" (tradename) absorbent resin, recovery of 97.5% pure product | FARMABIOS S.P.A. (IT) | 2011-01-18 | — | — | US | disclosed |
| US-7872137-B2 | coupling of N-3-hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride with (E)-4-octene-1,8-dioic acid dichloride, in a solvent(dichloromethane), to obtain raw mivacurium chloride, water extraction of raw product, treatment with amberlite\" (tradename) absorbent resin, recovery of 97.5% pure product | FARMABIOS S.P.A. (IT) | 2011-01-18 | — | — | US | disclosed |
| US-20070293534-A1 | Process for the preparation of mivacurium chloride | FARMABIOS S.P.A. | 2007-12-20 | — | — | US | disclosed |
| US-20070293534-A1 | Process for the preparation of mivacurium chloride | FARMABIOS S.P.A. | 2007-12-20 | — | — | US | disclosed |
| US-20070293534-A1 | Process for the preparation of mivacurium chloride | FARMABIOS S.P.A. | 2007-12-20 | — | — | US | disclosed |
| US-4761418-A | NEUROMUSCULAR BLOCKING AGENTS | BURROUGHS WELLCOME CO. (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0181055-A1 | Bis-dimethoxymethyl (trimethoxybenzyl)isoquinolinium salts, their preparation and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | TSHR 4621/4885ALDH1A1 4312/4885TP53 78/4885 |
| US-20070293534-A1 | Process for the preparation of mivacurium chloride | CHRNE, CHRNA9, CHRNB4 | TSHR 1480/4885ALDH1A1 3029/4885TP53 4870/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | TSHR 4630/4885ALDH1A1 4127/4885TP53 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.